Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Sutro Biopharma (STRO) Stock Price & Analysis
523 Followers
STRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.01 - $6.13
Previous Close$4.16
Volume1.06M
Average Volume (3M)829.82K
Market Cap
$340.26M
Enterprise Value$55.12M
Total Cash (Recent Filing)$313.22M
Total Debt (Recent Filing)$28.07M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 08, 2024EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding81,794,334
10 Day Avg. Volume723,156
30 Day Avg. Volume829,820
Standard Deviation0.18
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)20.31
Price to Cash Flow (P/CF)4.70
P/FCF Ratio3.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit0.36
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$10.43Price Target Upside147.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Sutro Biopharma News
PremiumStock Analysis & Ideas
Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Clinical TrialsLuvelta shows promise in pediatric AML, demonstrating anti-leukemic activity in patients with a rare aggressive leukemia.
Financial PerformanceA solid cash position of $371.1 million supports the belief that Sutro represents a unique investment opportunity.
Partnerships And CollaborationsSutro Biopharma continues to have multiple marquee partners progressing candidates through development.
Bears Say
CatalystsThere is a lack of near-term catalysts in the next 12 months as the company advances its registrational programs.
Clinical TrialsPart 1 REFRaME-01 enrollment to be complete in 1H24 with unclear outcomes for the initial 50 patients.
Development PlansSutro does not intend to pursue development of STRO-001 further, following the termination of BioNova’s collaboration agreement.
---
Ownership Overview
18.15% Insiders
11.13% Mutual Funds
40.12% Other Institutional Investors
30.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $2.00 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Currently, no data Available
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Aug 08, 2024 which is in 22 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on May 13, 2024. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.922 by -$0.028.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -$0.79.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 81,794,334 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.922. Following the earnings report the stock price went up 2.6%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Among the largest hedge funds holding Sutro Biopharma Inc’s share is Fisher Asset Management LLC. It holds Sutro Biopharma Inc’s shares valued at 1M.
---
Sutro Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.43 (147.16% Upside)
$10.43 (147.16% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 86.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.48%
12-Months-Change
Fundamentals
Return on Equity
-81.12%
Trailing 12-Months
Asset Growth
12.68%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.43
▲(147.16% Upside)
Technical Analysis
Best Analysts Covering STRO
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+4.36%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +4.36% per trade.
---